ZyVersa Therapeutics (ZVSA) Competitors $0.70 -0.04 (-5.42%) Closing price 03/27/2025 03:51 PM EasternExtended Trading$0.69 -0.01 (-1.99%) As of 03/27/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. BFRI, OMGA, ALZN, ALBT, GTBP, SNGX, AEZS, CANF, FRTX, and OGENShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Biofrontera (BFRI), Omega Therapeutics (OMGA), Alzamend Neuro (ALZN), Avalon GloboCare (ALBT), GT Biopharma (GTBP), Soligenix (SNGX), Aeterna Zentaris (AEZS), Can-Fite BioPharma (CANF), Fresh Tracks Therapeutics (FRTX), and Oragenics (OGEN). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Biofrontera Omega Therapeutics Alzamend Neuro Avalon GloboCare GT Biopharma Soligenix Aeterna Zentaris Can-Fite BioPharma Fresh Tracks Therapeutics Oragenics Biofrontera (NASDAQ:BFRI) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Do institutionals and insiders believe in BFRI or ZVSA? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.2% of Biofrontera shares are held by company insiders. Comparatively, 0.3% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to BFRI or ZVSA? In the previous week, Biofrontera had 5 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 11 mentions for Biofrontera and 6 mentions for ZyVersa Therapeutics. Biofrontera's average media sentiment score of 0.54 beat ZyVersa Therapeutics' score of 0.31 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ZyVersa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BFRI or ZVSA? Biofrontera currently has a consensus price target of $7.00, indicating a potential upside of 725.76%. Given Biofrontera's stronger consensus rating and higher possible upside, analysts clearly believe Biofrontera is more favorable than ZyVersa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, BFRI or ZVSA? Biofrontera has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Is BFRI or ZVSA more profitable? ZyVersa Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. ZyVersa Therapeutics' return on equity of -224.85% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-36.31% -565.73% -96.64% ZyVersa Therapeutics N/A -224.85%-103.22% Which has preferable valuation and earnings, BFRI or ZVSA? Biofrontera has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$37.32M0.20-$20.13M-$2.26-0.38ZyVersa TherapeuticsN/AN/A-$98.30MN/AN/A Does the MarketBeat Community believe in BFRI or ZVSA? Biofrontera received 5 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 66.67% of users gave Biofrontera an outperform vote. CompanyUnderperformOutperformBiofronteraOutperform Votes866.67% Underperform Votes433.33% ZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo Votes SummaryBiofrontera beats ZyVersa Therapeutics on 10 of the 15 factors compared between the two stocks. Remove Ads Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.64M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E RatioN/A7.2023.1319.03Price / SalesN/A226.00383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.016.476.944.33Net Income-$98.30M$141.90M$3.20B$247.06M7 Day Performance-0.16%-3.05%-2.30%-0.52%1 Month Performance-40.18%-4.63%3.10%-3.73%1 Year Performance-91.00%-8.61%11.22%1.74% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.3349 of 5 stars$0.70-5.4%N/A-91.0%$1.64MN/A0.002Upcoming EarningsShort Interest ↑News CoverageBFRIBiofrontera2.3262 of 5 stars$0.90+4.8%$7.00+676.7%-26.3%$6.98M$35.36M-0.4070Short Interest ↑OMGAOmega Therapeutics1.9632 of 5 stars$0.13-21.8%$9.20+7,260.0%-96.5%$6.92M$8.10M-0.09120Gap UpALZNAlzamend Neuro3.5164 of 5 stars$1.02+1.0%$20.00+1,860.8%-89.2%$6.73MN/A0.004Short Interest ↓Gap UpALBTAvalon GloboCare2.2435 of 5 stars$5.97-5.1%N/A+16.6%$6.53M$1.31M-0.305Short Interest ↓Gap DownGTBPGT Biopharma3.7314 of 5 stars$2.33-6.8%$11.00+372.1%-48.7%$5.91MN/A-0.338Short Interest ↓SNGXSoligenix1.4927 of 5 stars$2.29-4.2%N/A-76.6%$5.75M$840,000.00-0.3020Earnings ReportShort Interest ↓Analyst RevisionGap DownAEZSAeterna ZentarisN/A$3.20-6.7%N/A-61.4%$5.74M$2.37M-0.2220Analyst ForecastGap DownHigh Trading VolumeCANFCan-Fite BioPharma2.1985 of 5 stars$1.62+1.3%$14.00+764.2%-31.9%$5.74M$667,000.00-0.918Gap UpHigh Trading VolumeFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+3.9%$5.59M$10.06M-0.6620OGENOragenicsN/A$0.26flatN/A-83.3%$5.58M$40,000.00-0.045 Remove Ads Related Companies and Tools Related Companies BFRI Alternatives OMGA Alternatives ALZN Alternatives ALBT Alternatives GTBP Alternatives SNGX Alternatives AEZS Alternatives CANF Alternatives FRTX Alternatives OGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
